This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Japan Biosimilars - ¥200b Worth Of Biologic Products Going Off Patent By 2015

MUMBAI, India, February 12, 2013 /PRNewswire/ --

Bharat Book Bureau has announces the release of its latest report - Therapeutic Class Report Overview - Japan Biosimilars

( http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/therapeutic-class-report-overview-japan-biosimilars.html)

Abstract

¥200b worth of biologic products is going off patent by 2015 and this value exceeds ¥500b if we include products that will see their patent expiries by 2021 in Japan. There are a number of reasons to believe that follow-on-biologics or biosimilars will not replicate the lethargic growth story of generic - preliminary because the much higher cost of biologic therapy brings significant burden on patients despite relatively low co-pay in Japan - and this will push individuals and DPC Hospitals to use biogeneric products to a greater extent unlike generic drugs. Secondly, the regulatory supports are going to be stringent enough to ensure quality measures and leave no room for imported products, thus eliminating the 'not made in Japan' factor from prescribers' and users' mindsets.

     (Logo: http://photos.prnewswire.com/prnh/20130128/590935 )

Anticipating this opportunity and favorable macro forces as compared to generics, a number of companies aim to exploit this - Japan has seen a flood like consolidation and partnering activities in biosimilar space. While a dozen+ companies have already laid their road map for biosimilars space, at this time we see Sandoz, JCR, Meiji Seika Pharma, Fuji Film Kyowa Kirin Biologics, Nippon Kayaku, Nichi Iko, Yoshindo etc. to be amongst the key players in biogenerics business in Japan.

In this piece, we attempt to evaluate the future competitive landscape of the biosimilars space in Japan, assess the overall attractiveness of the same, and try to identify the key determinates to succeed in this space.

Request for Sample pages - http://www.bharatbook.com/RequestSample.asp?pid=371870

Table of Contents

Investment Thesis Opening biosimilar opportunity in Japan in next decade Key local players Consolidation trend in biogeneric space Expected market penetration - Does it will repeat the lethargic growth story of small molecule generics in Japan? Evolving Biogeneric landscape in  Japan Launched biogenerics in Japan and their uptake trend Top 10 small molecules vs. Top 10 biologics in Japan Likely launch schedule of select biosimilars Japan Specific Hurdles & Drivers Biogeneric opportunity, it's likely profitability vs. risk profile Development cost of biosimilars vs. small molecules Price difference vs. small molecules and DPC hospitals business are key drivers -Co-pay Slabs in Japan -Saving through biosimilar use -Pricing of key biologics in Japan Regulatory Guidelines: Stringent Enough to Restrict Scope of Import Korosho guidelines- Key difference vs. US, EU JP requirement of -Reference Product -Interchangeability/Substitution -Pharmacovigilance -PMS for biosimilar

Select Japanese Companies venturing into biogeneric space  -  Their strategy and Pipeline

JCR Pharmaceuticals

Meiji Seika Pharma

Fuji Film Kyowa Kirin Biologics

Nichi Iko

Mochida

Nipro Pharma

Yoshindo

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs